BeiGene (NASDAQ: BGNE), a Chinese pharmaceutical company, saw its shares rise more than 10% in early trading on Friday. The company has been on a roll lately with its lead oncology drug, Brukinsa (zanubrutinib). On Wednesday, BeiGene said that the Food and Drug Administration had granted accelerated approval to Brukinsa as a therapy for patients with relapsed or refractory marginal zone lymphoma who have already had at least one regimen of an anti-CD20-based antibody treatment.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting